MLK
Las MLK (Mixed-Lineage Kinases) son un grupo de quinasas que pueden activar múltiples vías MAPK, incluidas JNK y p38, al fosforilar quinasas MAP aguas arriba (MAP2K). Las MLK están involucradas en las respuestas celulares al estrés, la apoptosis y la neuroinflamación. La desregulación de la actividad de las MLK está asociada con enfermedades neurodegenerativas y ciertos cánceres. En CymitQuimica, ofrecemos una gama de moduladores de MLK de alta calidad para apoyar su investigación en neurobiología, respuesta al estrés y transducción de señales.
Se han encontrado 21 productos para "MLK".
Filtrar por
Porcentaje de pureza
0
100
|
0
|
50
|
90
|
95
|
100
- Precio más bajo
- Precio más alto
- Pureza más baja
- Pureza más alta
- Entrega estimada más rápida
GW806742X
CAS:GW806742X inhibits MLKL with Kd 9.3 μM, preventing necroptosis; also targets VEGFR2.Fórmula:C25H22F3N7O4SPureza:98.3%Forma y color:SolidPeso molecular:573.547MLKL-IN-2
CAS:MLKL-IN-2 is an MLKL inhibitor with potential tumorigenic activity for the study of cellular necrosis-related diseases.Fórmula:C26H25N5OPureza:99.24%Forma y color:Yellow SolidPeso molecular:423.5096Necrosulfonamide-D4
CAS:Necrosulfonamide-D4 is the deuterated form of Necrosulfonamide. Necrosulfonamide (T6904) acts as a necroptosis inhibitor by selectively targeting (MLKL). It hinders the interaction between the MLKL-RIP1-RIP3 necrosome complex and its downstream effectors. MLKL serves as a crucial substrate of RIP3 in the necrosis induction process.Fórmula:C18H15N5O6S2Peso molecular:465.50MLKL-IN-7
MLKL-IN-7 (compound 9) is an MLKL inhibitor that exhibits anti-necrotic activity in HT-29 cells, with an IC50 value of 148.4 nM.Fórmula:C21H15N5O5S2Forma y color:SolidPeso molecular:481.05146Anticancer agent 267
Anticanceragent 267 (Compound 5q) serves as an activator of RIPK3 and MLKL. It effectively inhibits the proliferation of several cancer cell lines, with IC50 values of 9.79, 10.77, and 5.94 μM for MDA-MB-231, MDA-MB-486, and MCF-7, respectively. The compound induces cell cycle arrest at the subG1 phase and triggers necroptosis in MDA-MB-231 cells. Additionally, Anticanceragent 267 demonstrates antitumor activity in mouse xenograft models.Fórmula:C13H11N5O4SForma y color:SolidPeso molecular:333.32PROTAC MLKL Degrader-1
PROTAC MLKL Degrader-1 (Compound 36) is a selective PROTAC degrader targeting MLKL, achieving a degradation maximum (D max) over 90%.Fórmula:C46H55F2N9O9SForma y color:SolidPeso molecular:948.05CEP1347-VHL-02
CEP1347-VHL-02 is a PROTAC that selectively targets MLK3. This compound is composed of the target protein ligand CEP-1347, the E3 ubiquitin ligase ligand (S,R,S)-AHPC-Me, and the PROTAC linker Amino-PEG3-CH2COOH. The participating component responsible for controlling the target protein ligand activity is CEP-1347-acid, whereas the conjugate of the E3 ubiquitin ligase ligand and linker is identified as (S,R,S)-AHPC-Me-CO-CH2-PEG3-NH2.Fórmula:C61H72N8O11S3Forma y color:SolidPeso molecular:1189.47NecroX-2
CAS:NecroX-2 is a cell-permeable necrosis inhibitor with antioxidant properties. NecroX-2 selectively suppresses necrotic cell death triggered by oxidative stress. NecroX-2 does not confer protection against apoptosis induced by staurosporine or etoposide but shows protective effects under conditions such as cold shock, hypoxia, and oxidative stress in vitro.Fórmula:C25H32N4O4S2Pureza:97.12%Forma y color:SolidPeso molecular:516.68PROTAC MLKL Degrader-2
PROTAC MLKL Degrader-2, a PROTAC that targets MLKL (Mixed Lineage Kinase), incorporates the PROTAC target protein ligand, E3 ligase ligand Thalidomide, and PROTAC Linker N-Methylpiperazine. The conjugate of the E3 ubiquitin ligase ligand and Linker is Thalidomide-N-Methylpiperazine. This compound exhibits antinecroptotic activity in human cell lines and effectively degrades MLKL in the HT-29 xenograft mouse model.Fórmula:C36H35N9O9SForma y color:SolidPeso molecular:769.78RIPK3-IN-3
RIPK3-IN-3 (compound 20) is a selective RIPK3 inhibitor that demonstrates potent activity with an IC50 value of 10 nM.Fórmula:C16H11N5SForma y color:SolidPeso molecular:305.36MLK-IN-1
CAS:MLK-IN-1 is a potent and selective mixed-lineage kinase 3 (MLK-3) inhibitor, showing excellent brain penetration and high specificity for MLK-3. MLK-IN-1 at 100 nM supports sustained axonogenesis in cultures challenged with HIV-1 Tat-activated microglia and protects neuronal cells from Tat-induced damage, establishing it as a valuable probe for neuroinflammation and neurodegeneration research.Fórmula:C23H20N4O3SPureza:99.74%Forma y color:Yellow SolidPeso molecular:432.495Necrosulfonamide
CAS:Necrosulfonamide ((E)-Necrosulfonamide) is a necroptosis inhibitor that targets MLKL and is selective. High-Quality, Low-Cost!Fórmula:C18H15N5O6S2Pureza:98.85% - 99.42%Forma y color:SolidPeso molecular:461.472MLKL-IN-5
CAS:MLKL-IN-5 is a potent MLKL inhibitor blocking necroptosis signaling.Fórmula:C18H20N6O4SPureza:98.77%Forma y color:Pink SolidPeso molecular:416.45SZM-1209
CAS:SZM-1209 is a potent and specific RIPK1 inhibitor with oral activity, displaying a dissociation constant (Kd) of 85 nM.Fórmula:C31H29F5N4O5S2Pureza:98%Forma y color:SolidPeso molecular:696.71IM-54
CAS:IM-54 is a cell-permeable, effective, and selective necrosis inhibitor.Fórmula:C19H23N3O2Pureza:99.24%Forma y color:SolidPeso molecular:325.4048TC13172
CAS:TC13172 is a potent, covalent MLKL inhibitor, selective over RIPK1/RIPK3. It blocks TSZ-induced necroptosis (EC50=2nM) and MLKL oligomerization at 100nM.Fórmula:C17H16N4O5SPureza:98%Forma y color:White SolidPeso molecular:388.398MLKL-IN-1
MLKL-IN-1 is a covalent inhibitor of MLKL with a Kd value of 50 μM.Fórmula:C19H20N2O3Forma y color:SolidPeso molecular:324.37Topoisomerase I/II inhibitor 8
CAS:TopoisomeraseI/II inhibitor 8 (Compound Ru7) is a dual catalytic inhibitor of TopoisomeraseI/II that induces DNA damage and activates PARP-1, leading to the activation of RIPK1, RIPK3, and MLKL, ultimately causing necroptosis. It shows significant anticancer activity by effectively targeting cancer cell nuclei and inducing cell death through necroptosis, offering substantial clinical potential in overcoming resistance in cancer treatment.Fórmula:C14H11Br2NO5S2Forma y color:SolidPeso molecular:497.179RIPK1-IN-34
CAS:RIPK1-IN-34 is a selective RIPK1 inhibitor capable of penetrating the blood-brain barrier with an IC50 of 126.70 nM, showing minimal inhibition of RIPK3 (IC50 > 10,000 nM). It exerts significant neuroprotective effects by inhibiting the phosphorylation of RIPK1, RIPK3, and mixed lineage kinase domain-like pseudokinase (MLKL) in the necroptosis pathway. RIPK1-IN-34 demonstrates neuroprotective effects in rat models of middle cerebral artery occlusion (MCAO) and is a candidate for research in the treatment of acute ischemic stroke (AIS).Fórmula:C28H25N7O2Peso molecular:491.56MLKL-IN-6
MLKL-IN-6 (compound P28) is a mixed lineage kinase inhibitor that specifically targets the Mixed Lineage Kinase domain-like (MLKL) protein.Fórmula:C20H18N4O5Pureza:98%Forma y color:SolidPeso molecular:394.38
